A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Phase 1

Terminated

• Conditions: Healthy; Dermatitis, Atopic
• Interventions: Drug: Placebo; Drug: LY3844583

• Registration Number: NCT05486208
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis. The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 88, 116, and 186 days with 10, 13, and 14 visits for each participant in parts A, B, and C, respectively.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-08-02
• Study First Submitted QC: 2022-08-02
• Study First Posted: 2022-08-03
• Study Start: 2022-08-11
• Primary Completion: 2024-01-20
• Study Completion: 2024-01-20
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-09
• Last Update Posted: 2024-05-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

• Healthy participants (Parts A and B):

  • Are male or female not of childbearing potential
  • inclusion of healthy Japanese participants, the participant must be first-generation Japanese, defined as the participant's biological parents and all of the participant's biological grandparents must be of exclusive Japanese descent, and must have been born in Japan.
  • inclusion of healthy Chinse participants, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participants' biological grandparents must be of exclusive Chinese descent and born in China.
  • Must have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive. For healthy Japanese participants, have a body mass index of 18.0 to 28.0 kg/m², inclusive, and a body weight of 50 kg to 85 kg, inclusive.

• Atopic dermatitis participants (Part C):

  • Must have a body mass index of 18.0 to 45.0 kg/m², inclusive
  • Are male or female participants including those of child bearing potential
  • Must have a diagnosis of AD for at least 12 months with either poor response to topical treatments or inability to use topical treatments
  • Must agree to use moisturizer daily throughout the treatment period

Exclusion Criteria

• All participants:

  • Have or used to have health problems or laboratory test results or electrocardiogram (ECG) readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Have active or latent tuberculosis
  • Have had any cancer within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrence or metastatic disease within the 3 years prior to baseline
  • Have one of the following viral infections: hepatitis B virus, hepatitis C virus or human immunodeficiency virus.
  • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 30 days or 5 half-lives (whichever is longer) prior to dosing
  • Must not have previously completed a clinical trial with a molecule targeting interleukin-33 and/or the interleukin-33 receptor (ST2)
  • Are currently participating in or completed a clinical trial within the last 30 days
  • Have received a vaccine containing a live (attenuated) virus within 28 days of screening or intend to receive during the course of the study

• Atopic dermatitis participants:

  • Must not have received certain topical medications for AD within 2 weeks prior to randomization
  • Must not have received certain oral medications for AD or received phototherapy within 4 weeks prior to randomization
  • Must not have received any antibody-based biologic agents (marketed or investigational) within 5 half lives (t1/2) of the drug prior to randomization
  • Must not have received intravenous, intramuscular, or intra-articular steroids in the past 6 weeks prior to randomization

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo (Part C)	Placebo	Placebo administered SC and/or IV.
LY3844583 (Part A)	LY3844583	Single doses of LY3844583 administered subcutaneously (SC) and/or intravenously (IV).
LY3844583 (Part B)	LY3844583	Multiple doses of LY3844583 administered SC and/or IV.
LY3844583 (Part C)	LY3844583	Repeat doses of LY3844583 administered SC and/or IV.
Placebo (Part A)	Placebo	Placebo administered SC and/or IV.
Placebo (Part B)	Placebo	Placebo administered SC and/or IV.

Primary Outcome Measures

Name	Time	Method
Number of Participants with One or More Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Baseline up to Day 186	A summary of AEs, TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

Secondary Outcome Measures

Name	Time	Method
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3844583	Pre-dose on Day 1 up to 186 days post-dose	PK: AUC of LY3844583
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583	Pre-dose on Day 1 up to 186 days post-dose	PK: Cmax of LY3844583

Trial Locations

Locations (3)

Medical Corporation Heishinkai OPHAC Hospital; 🇯🇵 Osaka-shi, Osaka, Japan

P-one clinic; 🇯🇵 Hachioji, Tokyo, Japan

Parexel Early Phase Unit at Glendale; 🇺🇸 Glendale, California, United States